'Dialysis-free' cure for kidney patients is closer

A new implantable device called Holly could revolutionize kidney disease treatment, potentially eliminating the need for dialysis for millions of patients worldwide. Developed by urologists Dr Nikhil Shah and Dr Hiep Nguyen at Atlanta-based medical device company Nephrodite, Holly received a breakthrough device designation from the FDA in 2025 following successful animal studies conducted on living sheep.

India faces one of the largest burdens of kidney disease globally, with more than two lakh new cases diagnosed annually. Only 6 to 10 percent of these patients receive dialysis, and barely one percent undergo kidney transplants. Dialysis patients must visit hospitals two to three times a week, endure repeated needle pricks, and structure their lives around these sessions, severely limiting travel, employment, and daily activities.

Holly is designed to filter waste continuously, functioning like a normal kidney. Surgically placed inside the body and connected to blood vessels in the pelvis, it filters waste around the clock. A bedside machine removes water at a time convenient for the patient, typically at night. Dr K S Nayak, director of nephrology at Gleneagles Fortis Hospital, Hyderabad, believes Holly could significantly improve quality of life, allowing patients to work, travel, and maintain normal daily routines.

The device is currently in pre-clinical phase, with an animal study expected in 2027 before human trials begin in India. The FDA has given its approval for human trials following promising results from sheep studies. Holly is already being manufactured in Kochi, Bengaluru, and Mumbai, with the goal of developing a scalable artificial kidney to reduce dependence on dialysis centers and improve global access to kidney replacement therapy.

Doctors remain optimistic about this new technology, hoping it will make dialysis simpler and more convenient, giving kidney failure patients greater freedom.